Organization
Tübingen, Germany
4 abstracts
Abstract
Multiomic factor analysis for pathologic complete response (pCR) after 12 weeks of pembrolizumab + trastuzumab + pertuzumab in HER2-enriched (HER2-E) early breast cancer (eBC) in the Keyriched-1 trial.Org: West German Study Group, Moenchengladbach, Germany, Queen Mary University of London, London, United Kingdom, Medical School Brandenburg, Institute for Biometrics and Registry Research, Neuruppin, Neuruppin, Germany,
Abstract
Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from the CheckMate 901 trial.Org: Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Dana-Farber Cancer Institute, Harvard Medical School, Barts Cancer Institute,
Abstract
EGFR expression and relapse in patients with melanoma receiving adjuvant PD-1-based immunotherapy.Org: Skin Cancer Center, University Hospital Leipzig, Department of Dermatology, Eberhard Karls University of Tuebingen, Tübingen, Germany, Kantonsspital St. Gallen,
Abstract
Interim analysis of MelaRisk, a biomarker assay validation study in stage IB/IIA melanoma tissue.Org: Center for Dermatooncology, Department of Dermatology, Eberhard Karls University of Tuebingen, Tuebingen, Germany, Tübingen, Germany,